A forecast cut
On Wednesday, Smith+Nephew lowered its 2026 revenue and profit forecast after its orthopaedics business, its largest division, posted weaker-than-expected third-quarter growth. Shares of the FTSE 100 company fell 1.7% in early trade.
The orthopaedics business, which accounts for about 40% of the company’s annual sales, has struggled for years, prompting management to seek options for the unit.
Smith+Nephew expects growth in orthopaedics to keep slowing through the final quarter of the year.

















